Palisade Bio, Inc., a clinical-stage biopharmaceutical company, reported significant financial developments in its recent 10-K filing for the fiscal year ending December 31, 2025. The company recorded an operating loss of approximately $18.1 million, a 22% increase from the previous year's loss of $14.9 million. This increase was primarily driven by a rise in research and development expenses, which grew by 12% to $10.2 million, largely due to increased clinical trial-related costs associated with its lead product candidate, PALI-2108. General and administrative expenses also rose by 36% to $7.9 million, reflecting higher employee-related costs and professional fees.
Palisade Bio's financial position improved significantly following a successful public offering in October 2025, which generated net proceeds of approximately $127.6 million. This capital infusion is expected to support the company's operations through key clinical development milestones, including a Phase 2 primary efficacy readout for PALI-2108 in ulcerative colitis (UC) anticipated in the second half of 2027, and a similar readout for Crohn's disease (CD) expected in 2028. As of December 31, 2025, the company reported cash, cash equivalents, and restricted cash totaling $133.4 million, a substantial increase from $9.8 million at the end of 2024.
In terms of strategic developments, Palisade Bio entered into a research collaboration and license agreement with Giiant Pharma, which grants the company exclusive rights to develop and commercialize PALI-2108. The agreement includes milestone payments and ongoing royalties based on sales, with the first milestone achieved in October 2025 when the company dosed its first patient in a Phase 1b trial for fibrostenotic Crohn's disease. The company also announced a funding agreement with the Crohn’s & Colitis Foundation, which could provide up to $0.5 million to support its research program related to PALI-2108.
Operationally, Palisade Bio has made progress in its clinical trials, with positive results reported from its Phase 1 study of PALI-2108 in UC patients. The company has also expanded its workforce, increasing its employee count to 14 as of March 2026, which includes personnel focused on research and development as well as corporate strategy. The company anticipates that its clinical research and development costs will continue to rise as it advances PALI-2108 through further clinical studies.
Looking ahead, Palisade Bio's management expressed confidence in its ability to fund operations through the anticipated milestones and ongoing clinical trials. However, the company acknowledged the inherent risks in drug development, including the potential for unforeseen challenges that could delay or prevent the commercialization of PALI-2108. The company remains focused on securing additional funding as needed to support its growth and development objectives.
About PALISADE BIO, INC.
Palisade Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases. Its lead candidate, PALI-2108, targets inflammatory bowel disease (IBD), including ulcerative colitis and fibrostenotic Crohn’s disease, using a localized PDE4 inhibitor prodrug approach. The company focuses on precision medicine, strategic collaborations, and advancing drug candidates through clinical trials to address unmet medical needs.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.